Nov 13, 2024 · Building a sustainable biopharma company that invests in, develops and commercializes life-changing innovative therapeutics and transformative medicines.

5 days ago · ACELYRIN. ACELYRIN is advancing lonigutamab, a subcutaneously delivered anti-IGF-1R with best-in-class potential in thyroid eye disease (TED) currently being investigated in a Phase 2 clinical trial. Lonigutamab is the first subcutaneous anti-IGF-1R to have demonstrated robust efficacy in TED patients, comparable to the IV-administered standard ...

5 days ago · Information about ACELYRIN’s directors and executive officers is set forth in the proxy statement for ACELYRIN’s 2024 Annual Meeting of Stockholders, which was filed with the SEC on April 22 ...

4 days ago · With Acelyrin sitting on $448 million in cash and equivalents and Alumis bringing $289 million to the table, Alumis expects that postmerger it will have a cash runway into 2027.

5 days ago · Prior to the merger, Acelyrin and Alumis were struggling with depressed share prices. The two biotechs went public in 2023 and 2024, respectively, in large initial public offerings — Acelyrin netted $540 million, while Alumis raised $250 million — but both have since lost most of their market value. Acelryin has already changed up its strategy.

5 days ago · Alumis and Acelyrin announced a definitive merger agreement under which Alumis and Acelyrin will merge in an all-stock transaction.Alumis and Acelyrin had cash, cash equivalents and marketable ...

Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

Jan 5, 2023 · ACELYRIN, INC. is a Los Angeles area-based late-stage clinical biopharmaceutical company – with additional operations in the San Francisco Bay area – focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development and commercialization of promising drug candidates.

We are exploring innovative approaches in immunology where we have the opportunity to make a clinically meaningful difference for patients relative to standard of care. We are led by experienced biopharma executives with exceptional track records of building strong, innovative and diverse teams across the healthcare industry.

4 days ago · Acelyrin, based in Los Angeles, raised $540 million in a 2023 IPO, but its lead drug failed a Phase IIb/III trial in the eye disease uveitis. It cut a third of its staff last year and trimmed its ...